Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial
경증 또는 중등도의 COVID-19 폐렴으로 입원한 환자를 위한 염증 신호 억제제(MATIS)의 다군 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] 24 hours
accounted
Administered
age
agreement
All participants
Allergic reactions
approved
baseline
blind
blinded
Blinding
block
Breastfeeding
Caregivers
cell proliferation
childbearing potential
clinical
clinical outcomes
clinically suspected
college
comparator
completion
Compliance
Concomitant medication
Contraception
Controlled trial
coronavirus
COVID-19
COVID-19 disease
COVID-19 pneumonia
CPAP
CRP
Data monitoring committee
Day
death
defined
Desaturation
determine
diagnosed
disease
disease severity
dissemination
dose
drug
ECMO
effective
Efficacy
element
English
enrolment
exclusion
experimental arm
experimental intervention
facemask
FOS
fostamatinib
generate
GRADE
grade 3
Graft
graft-versus-host-disease
hepatic dysfunction
hospital
Hospital admission
Hospital stay
hospitalisation
hospitalised patient
Hospitalised patients
Immune thrombocytopenia
Imperial College Healthcare NHS Trust
incidence
information
Informed consent
inhibitor
Inpatient
Inpatients
Intervention
invasive
Invasive mechanical ventilation
invasive ventilation
investigational agent
investigator
JAK1
JAK2
janus
kinase
Kinase inhibitor
kinases
Laboratory
male participants
MATIS
Mild
minimum
moderate
Moderate COVID-19
moderate to severe
Modification
multi-arm
myelofibrosis
nasal oxygen
NHS
Non-invasive
non-invasive ventilation
number
objective
Obstructive
obstructive sleep apnoea
opinion
Ordinal Scale
outcome
oxygen
Pairwise comparison
pandemic
parallel-group
participant
Patient
Pneumonia
polycythaemia vera
principal investigator
product
progression
promise
proportion
protocol
random
randomisation
randomised
randomised controlled trial
receiving
recruit
recruited
reduce
reduce mortality
reducing
renal impairment
renal replacement therapy
replacement therapy
required
Requirement
ruxolitinib
Sample size
sample size calculation
Sample size calculations
SARS-CoV2 infection
scale
Secondary objectives
selective
sequence
severe allergic reaction
Severe COVID-19 pneumonia
severity
severity of COVID-19
sexual intercourse
signal
sleep apnoea
Sperm
sperm donation
spleen
Splenomegaly
Stage
stage 2
Standard
Standard of care
statistical analysis
status
Stratification
study drug
Study protocol
supplementary material
Symptom
systemic inflammation
the WHO
therapy
thrombocytopenia
translation
Treatment
Trial
Trial registration
Trust
tyrosine
tyrosine kinase inhibitor
Venous Thromboembolism
verbal
website
WHO
with COVID-19
[DOI] 10.1186/s13063-021-05190-z PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-021-05190-z PMC 바로가기 [Article Type] Letter